Insider Buying: GSK (LON:GSK) Insider Buys 411 Shares of Stock

GSK plc (LON:GSK) insider Wendy Becker bought 411 shares of GSK stock in a transaction that occurred on Friday, March 20th. The shares were acquired at an average price of GBX 1,963 per share, with a total value of £8,067.93.

Wendy Becker also recently made the following trade(s):

• On Friday, February 20th, Wendy Becker bought 3,334 shares of GSK stock. The stock was acquired at an average cost of GBX 2,219 per share, with a total value of £73,981.46.

GSK Stock Down 0.6%

GSK stock traded down GBX 11.50 during midday trading on Monday, hitting GBX 1,939. The company’s stock had a trading volume of 886,705,000 shares, compared to its average volume of 25,118,266. The company’s fifty day moving average price is GBX 2,024.84 and its 200 day moving average price is GBX 1,817.34. The company has a debt-to-equity ratio of 108.20, a current ratio of 0.82 and a quick ratio of 0.73. GSK plc has a twelve month low of GBX 1,242.50 and a twelve month high of GBX 2,282. The stock has a market capitalization of £77.78 billion, a P/E ratio of 13.97, a PEG ratio of 1.24 and a beta of 0.32.

GSK (LON:GSK) last posted its quarterly earnings data on Wednesday, February 4th. The company reported GBX 172 EPS for the quarter. GSK had a net margin of 17.50% and a return on equity of 37.19%. As a group, equities research analysts predict that GSK plc will post 175.980975 EPS for the current year.

Analysts Set New Price Targets

GSK has been the topic of several recent analyst reports. Jefferies Financial Group reaffirmed a “buy” rating and set a GBX 2,100 price target on shares of GSK in a research report on Wednesday, January 7th. JPMorgan Chase & Co. reissued an “underweight” rating on shares of GSK in a report on Wednesday, January 7th. Citigroup raised their target price on shares of GSK from GBX 1,900 to GBX 2,250 and gave the company a “buy” rating in a research note on Monday, February 9th. UBS Group reaffirmed a “neutral” rating and set a GBX 1,940 price target on shares of GSK in a research report on Friday, January 23rd. Finally, Berenberg Bank increased their price target on shares of GSK from GBX 1,600 to GBX 1,660 and gave the company a “hold” rating in a research note on Monday, November 24th. Three investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of GBX 1,917.86.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.